Has Aisha Ahmed, MD received payments from drug or device companies?

Yes. Drug and device makers reported $1,551,960 in general payments to Aisha Ahmed, MD across 776 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Aisha Ahmed, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Aisha Ahmed, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Aisha Ahmed, MD

Hematology & Oncology · Tucson, AZNPI 1730341850

Payments from drug & device makers

$1,551,960in general payments, 2019–2025

Across 776 payments — averaging $1999.95 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

AstraZeneca$592K
Genentech, Inc.$409K
Merck$256K
Sanofi US Services Inc.$130K
Jazz Pharmaceuticals Inc.$57K
Eli Lilly$44K
plus $64K from 50 others

$2,006in research payments, 2019–2025

Across 1 payment — averaging $2006.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

Eli Lilly$2K

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
AstraZeneca(2 entities)	48	$591,811
Genentech, Inc.	297	$408,767
Merck	23	$256,499
Sanofi US Services Inc.	36	$129,587
Jazz Pharmaceuticals Inc.	23	$56,800
Eli Lilly	13	$44,127
Biontech SE	14	$41,222
Veru Inc.	4	$11,289
Daiichi Sankyo Inc.	14	$2,949
Pfizer	21	$2,222
Gilead(2 entities)	34	$1,499
Novartis	54	$892
Bristol Myers Squibb	33	$502
Johnson & Johnson	17	$376
Seagen Inc.	9	$297
Incyte Corporation	8	$269
Genentech USA, Inc.	11	$238
AbbVie	8	$167
Puma Biotechnology, Inc.	8	$152
Genmab U.S., Inc.	5	$140
Bayer	7	$128
Sobi, Inc	3	$117
Amgen	6	$110
Sanofi	5	$106
Stemline Therapeutics Inc.	5	$105
Lilly USA, LLC	6	$97
Sanofi-aventis U.S. LLC	1	$96
Sumitomo Pharma America, Inc.	4	$96
Takeda Pharmaceuticals U.S.A., Inc.	5	$94
Array Biopharma Inc	5	$90
Intuitive Surgical	1	$90
Regeneron Healthcare Solutions, Inc.	3	$87
Rigel Pharmaceuticals, Inc.	3	$85
Exelixis Inc.	4	$82
GSK	3	$71
EMD Serono, Inc.	3	$64
Eisai Inc.	3	$59
Pharmacosmos Therapeutics Inc.	2	$57
CTI Biopharma Corp.	2	$53
Beigene USA, Inc.	1	$50
Astellas Pharma US Inc	3	$49
Taiho Oncology, Inc.	2	$49
Dendreon Pharmaceuticals LLC	2	$46
Mirati Therapeutics, Inc.	3	$46
E.r. Squibb & Sons, L.L.C.	3	$42
GE HealthCare	1	$24
Kyowa Kirin, Inc.	1	$21
Pharmacyclics LLC, An Abbvie Company	1	$20
ADC Therapeutics America, Inc.	1	$20
Karyopharm Therapeutics Inc.	1	$18
Apellis Pharmaceuticals, Inc.	1	$17
Tempus AI, Inc	1	$15
Adaptive Biotechnologies Corporation	1	$14
G1 Therapeutics, Inc.	1	$13
Sun Pharmaceutical Industries Inc.	1	$13
Heron Therapeutics, Inc.	1	$11

How this compares

$1,551,960 in reported general payments places this provider in the 85th percentile of 261 hematology & oncology providers in Arizona.

See all hematology & oncology providers in Arizona →

Medicare billing

Part B allowed, 2024

$2,145,050

Medicare patients

523

Services billed

159,695

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other hematology & oncology in Tucson

Sudhir MandaTucson$10M
Rachna ShroffTucson$3M
Aaron ScottTucson$2.6M
Manuel Modiano RevahTucson$1.7M
Rachel SwartTucson$1.6M
Faiz AnwerTucson$1.3M
Alison StopeckTucson$1.3M
Ahmed AbdelazizTucson$962K
Ricklie JulianTucson$840K
Richard RosenbergTucson$778K

See the full list for Arizona →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →